(11) 98705-3426
TrademarkIQ íconeTrademarkIQ
Voltar para busca
Dado oficial do USPTO

ODYSSION

Sabia que essa marca já está registrada no Estados Unidos?

Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.

Active USPTO registrationTipo: VerbalEscritório: US

Snapshot rápido

ODYSSION

ST13

US500000079352298

Classe

1, 5, 42

Pedido

79352298

Registro

7296103

Diagnóstico de risco e oportunidade

Leitura executiva para decisão de naming, protocolo e monitoramento.

Atenção: há risco ativo

Situação USPTO

Active USPTO registration

Tipo de processo

Pedido e registro

Eventos registrados

31

Atualização mais recente

02/06/2024

Classificação

Registrada

Tipo de marca

Verbal

Classes Nice

1, 5, 42

Data de depósito

24/05/2022

Data de registro

06/02/2024

Data de expiração

-

Ação recomendada

Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.

Próximo passo

Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.

Dados completos do processo

Campos estruturados da autoridade responsável e do histórico oficial.

Data da situação

06/02/2024

Última transação

06/02/2024

Escritório responsável

United States Patent and Trademark Office

Código da situação

700

Cadastro oficial

Principal Register

Código do desenho

4

Tipo de titular

99

Localização do titular

GB

Examinador

ALLEN, BIANCA LEIGH

Unidade examinadora

N50

Localização atual

PUBLICATION AND ISSUE SECTION

Titulares e representantes

Titulares

OMASS Therapeutics Limited

Representantes

Rebecca Liebowitz Venable LLP

Classificação técnica

Classes Nice

Classe 1Classe 5Classe 42

Códigos Vienna

Sem códigos Vienna disponíveis.

Produtos e serviços

Classe 1

Reagents for use in medical research and scientific research being biological analysis; proteins for use in the manufacture of pharmaceuticals and reagents; proteins in raw material form for use in medical research; cells, cell lines, and cell cultures, all being cells for clinical laboratory use, for use in the production of proteins for therapeutic use

Classe 5

Pharmaceutical and veterinary preparations and substances for the treatment of immune response disorders, genetic conditions, cancer, ophthalmological conditions, hematologic diseases, neurological disorders, respiratory diseases, metabolic diseases, infectious diseases and cardiovascular diseases; biopharmaceutical preparations and substances for treatment of immune response disorders, genetic conditions, cancer, ophthalmological conditions, hematologic diseases, neurological disorders, respiratory diseases, metabolic diseases, infectious diseases and cardiovascular diseases; chemical, biochemical and biological preparations for medical and veterinary purposes for the treatment of immune response disorders, genetic conditions, cancer, ophthalmological conditions, hematologic diseases, neurological disorders, respiratory diseases, metabolic diseases, infectious diseases and cardiovascular diseases; cells, cell lines, and cell cultures, all being cells for medical use, for use in the production of proteins for therapeutic use; reagents for medical use, namely, proteins being medical therapeutic reagents; therapeutic antibodies; vaccines

Classe 42

Scientific and technological services, namely, scientific research and design relating thereto in the field of analytical sciences, biophysics, chemistry, biochemistry, biotechnology, molecular sciences and mass spectrometry; laboratory research services in the field of analytical sciences, biophysics, chemistry, biochemistry, biotechnology, molecular sciences and mass spectrometry; medical and pharmacological research services; scientific research, namely, scientific analysis and testing being measurement of substances in the field of analytical sciences, biophysics, chemistry, biochemistry, biotechnology, molecular sciences and mass spectrometry; scientific analysis and measurement of molecules and characteristics in the field of analytical sciences, biophysics, chemistry, biochemistry, biotechnology, molecular sciences and mass spectrometry; bioanalysis services; scientific imaging services; biochemical analysis; scientific research and development services; medical research and medical development services in the field of immunology, genetic conditions, oncology, immuno-oncology, ophthalmology, haematology, neurology, respiratory diseases, metabolic conditions, infectious diseases and cardiovascular diseases; pharmaceutical research and development services; biological research and analysis; biomedical research services; biotechnological research, namely, biotechnology scientific testing, in the biotechnical, biomedical and pharmaceutical fields; chemical research and analysis; research and development of new products for others in the biotechnical, biomedical and pharmaceutical fields; pharmaceutical research and development for the pharmaceutical industry; research and development of vaccines and medicines; scientific research and development services in the field of antibodies; scientific research and development services in the field of antibody technology; scientific research and development services in the field of immunology; medical laboratory services; research of pharmaceuticals; research relating to molecular sciences; research relating to pharmaceuticals; biopharmaceutical research, development and testing being product testing services; drug discovery services; product development, namely, drug development services; pharmaceutical drug development services; conducting early evaluations in the field of new pharmaceuticals; scientific research and development of molecules for therapeutic purposes; consultancy, advisory and information services in relation to all the aforesaid services

Publicações

Histórico de despachos e eventos da marca no USPTO.

31 publicações encontradas

FINO

FINAL DECISION TRANSACTION PROCESSED BY IB

02/06/2024

FICS

FINAL DISPOSITION NOTICE SENT TO IB

10/05/2024

FIMP

FINAL DISPOSITION PROCESSED

10/05/2024

FICR

FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB

06/05/2024

NRCC

NOTICE OF REGISTRATION CONFIRMATION EMAILED

06/02/2024

R.PR

REGISTERED-PRINCIPAL REGISTER

06/02/2024

GPNX

NOTIFICATION PROCESSED BY IB

21/11/2023

NPUB

OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED

21/11/2023

PUBO

PUBLISHED FOR OPPOSITION

21/11/2023

OPNS

NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB

01/11/2023

OP2R

NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB

01/11/2023

NONP

NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED

01/11/2023

CNSA

APPROVED FOR PUB - PRINCIPAL REGISTER

16/10/2023

XAEC

EXAMINER'S AMENDMENT ENTERED

16/10/2023

GNEN

NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED

16/10/2023

GNEA

EXAMINERS AMENDMENT E-MAILED

16/10/2023

CNEA

EXAMINERS AMENDMENT -WRITTEN

16/10/2023

ADCH

CHANGE OF NAME/ADDRESS REC'D FROM IB

07/10/2023

DOCK

ASSIGNED TO EXAMINER

18/09/2023

TEME

TEAS/EMAIL CORRESPONDENCE ENTERED

20/07/2023

CRFA

CORRESPONDENCE RECEIVED IN LAW OFFICE

19/07/2023

TROA

TEAS RESPONSE TO OFFICE ACTION RECEIVED

19/07/2023

RFNT

REFUSAL PROCESSED BY IB

24/05/2023

RFCS

NON-FINAL ACTION MAILED - REFUSAL SENT TO IB

04/05/2023

RFRR

REFUSAL PROCESSED BY MPU

04/05/2023

RFCR

NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW

16/03/2023

CNRT

NON-FINAL ACTION WRITTEN

15/03/2023

DOCK

ASSIGNED TO EXAMINER

13/03/2023

MAFR

APPLICATION FILING RECEIPT MAILED

18/10/2022

NWOS

NEW APPLICATION OFFICE SUPPLIED DATA ENTERED

14/10/2022

REPR

SN ASSIGNED FOR SECT 66A APPL FROM IB

13/10/2022

Proteção contínua da sua marca

Seja avisado a cada novo depósito que ameace ODYSSION ou a sua marca.

Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.